Turn Biotechnologies

Turn Biotechnologies is a biotechnology startup with the mission of developing longevity solutions to combat diseases of aging by restoring youthful performance to adult cells. Founded in 2019 and headquartered in the United States, the company aims to address multiple aging-related indications using a powerful reprogramming therapy that turns old cells young again, ultimately aiding in the rejuvenation of an aged human body.

A notable achievement of Turn Bio is the development of a proprietary cocktail of transiently-administered rejuvenation factors that have been demonstrated to reverse eight of the nine hallmarks of aging identified in a 2013 paper in Cell. This innovative approach aligns with the goal of "turning back time" and holds promise for addressing the root causes of aging-related diseases.

Investors in Turn Biotechnologies include Khosla Ventures, Astellas Venture Management, Formic Ventures, ThreeD Capital, LongeVC, Methuselah Funds, HanAll Biopharma, Daewoong Pharmaceutical, and the Shanda Group, who participated in the latest Venture Round investment on 11 April 2022. With its pioneering technology and strong investor backing, Turn Bio is poised to make significant strides in the biotechnology and healthcare industries.